NovoCure Limited Statistics
Share Statistics
NovoCure Limited has 108.20M shares outstanding. The number of shares has increased by 1.03% in one year.
| Shares Outstanding | 108.20M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.01% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 96.88M |
| Failed to Deliver (FTD) Shares | 623 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 5.19M, so 4.8% of the outstanding shares have been sold short.
| Short Interest | 5.19M |
| Short % of Shares Out | 4.8% |
| Short % of Float | 5.33% |
| Short Ratio (days to cover) | 3.09 |
Valuation Ratios
The PE ratio is -7.67 and the forward PE ratio is -11.88.
| PE Ratio | -7.67 |
| Forward PE | -11.88 |
| PS Ratio | 3.12 |
| Forward PS | 4.1 |
| PB Ratio | 4.38 |
| P/FCF Ratio | -15.82 |
| PEG Ratio | n/a |
Enterprise Valuation
NovoCure Limited has an Enterprise Value (EV) of 1.94B.
| EV / Earnings | -9.39 |
| EV / Sales | 3.82 |
| EV / EBITDA | -11.05 |
| EV / EBIT | -8.35 |
| EV / FCF | -19.36 |
Financial Position
The company has a current ratio of 5.78, with a Debt / Equity ratio of 1.64.
| Current Ratio | 5.78 |
| Quick Ratio | 5.56 |
| Debt / Equity | 1.64 |
| Total Debt / Capitalization | 62.19 |
| Cash Flow / Debt | -0.12 |
| Interest Coverage | -70.16 |
Financial Efficiency
Return on equity (ROE) is -0.57% and return on capital (ROIC) is -26.23%.
| Return on Equity (ROE) | -0.57% |
| Return on Assets (ROA) | -0.18% |
| Return on Capital (ROIC) | -26.23% |
| Revenue Per Employee | 350.54K |
| Profits Per Employee | -142.49K |
| Employee Count | 1.45K |
| Asset Turnover | 0.44 |
| Inventory Turnover | 3.36 |
Taxes
| Income Tax | 15.30M |
| Effective Tax Rate | -0.08 |
Stock Price Statistics
The stock price has increased by 108.82% in the last 52 weeks. The beta is 0.7, so NovoCure Limited's price volatility has been higher than the market average.
| Beta | 0.7 |
| 52-Week Price Change | 108.82% |
| 50-Day Moving Average | 24.62 |
| 200-Day Moving Average | 19.34 |
| Relative Strength Index (RSI) | 41.46 |
| Average Volume (20 Days) | 1.40M |
Income Statement
In the last 12 months, NovoCure Limited had revenue of 509.34M and earned -207.04M in profits. Earnings per share was -1.95.
| Revenue | 509.34M |
| Gross Profit | 381.06M |
| Operating Income | -232.87M |
| Net Income | -207.04M |
| EBITDA | -175.87M |
| EBIT | -232.87M |
| Earnings Per Share (EPS) | -1.95 |
Balance Sheet
The company has 240.82M in cash and 596.24M in debt, giving a net cash position of -355.42M.
| Cash & Cash Equivalents | 240.82M |
| Total Debt | 596.24M |
| Net Cash | -355.42M |
| Retained Earnings | -985.50M |
| Total Assets | 1.22B |
| Working Capital | 360.27M |
Cash Flow
In the last 12 months, operating cash flow was -73.34M and capital expenditures -27.09M, giving a free cash flow of -100.43M.
| Operating Cash Flow | -73.34M |
| Capital Expenditures | -27.09M |
| Free Cash Flow | -100.43M |
| FCF Per Share | -0.94 |
Margins
Gross margin is 74.81%, with operating and profit margins of -45.72% and -40.65%.
| Gross Margin | 74.81% |
| Operating Margin | -45.72% |
| Pretax Margin | -37.64% |
| Profit Margin | -40.65% |
| EBITDA Margin | -34.53% |
| EBIT Margin | -45.72% |
| FCF Margin | -19.72% |
Dividends & Yields
NVCR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -7.42% |
| FCF Yield | -3.53% |
Analyst Forecast
The average price target for NVCR is $38, which is 44.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $38 |
| Price Target Difference | 44.5% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 1.43 |
| Piotroski F-Score | 4 |